TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
DOE/Brookhaven National Laboratory
Addiction treatment proves successful in animal weight loss study
September 2nd, 2008
Vigabatrin, a medication proposed as a potential treatment for drug addiction by scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, also leads to rapid weight loss and reduced food intake according to a new animal study from the same research group. The study will be published online August 20, 2008, by the journal Synapse. Vigabatrin is currently undergoing U.S. Food and Drug Administration (FDA)-approved Phase II clinical trials against cocaine and methamphetamine addiction across the U.S. In the current study, animals genetically bred to be obese experienced a loss of up to 19 percent of their total weight while non-obese animals lost...
Source: TB & Outbreaks Week (2008-09-02)
|
